Therapeutic innovation.
The small but very focused meeting of 60 delegates from academia, small biopharmaceutical companies and large pharmaceutical companies aimed to give an overview of current R&D approaches in the cardiovascular disease area. Most of the new therapeutic approaches were presented by small biopharmaceutical companies and addressed disease targets in the vasculature for the following indications: thrombosis; atherosclerosis; restenosis; hyperlipidemia; and hypertension. Cardiac disease targets were addressed in the following indications: congestive heart failure (CHF); chronic angina; reperfusion injury; and atrial arrhythmia. The technologies presented included small molecule drugs, protein drugs and gene therapeutics as well as vaccines and an integrated target definition platform. The therapeutic approaches were complemented by the presentation of two innovative diagnostic products for thrombosis and stroke related brain injury.
Henkel
T
T
Molecular Cardiology Division, MediGene AG, Lochhamei Strasse 11, D-82152 Martinsried, Germany. henkel@medigene.de